Conatus Calls Down $22 Million

Conatus Pharmaceuticals, a San Diego-based drug company focused on inflammation and liver disease, has called down the final $22 million of its $27.5 million Series A round. The company had held a first close late last year, with the remainder tied to clinical milestones. Conatus was founded in July 2005 by the executive management team of Idun Pharmaceuticals, following the sale of Idun to Pfizer.